Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 02 Feb 2023 for Evelo Biosciences, Inc., €1,014. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Mark D. Plinio: trading record in brief
Mark D. Plinio (senior executive) discloses dealings in Evelo Biosciences, Inc. to SEC (Form 4). We count 3 filings; the first trade dates from 31 January 2022 and the latest from 31 January 2023.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The record was last updated on 2 February 2023 with a share grant (€1,014) in Evelo Biosciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Mark D. Plinio
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
1,250 shares@ US$0.888.3% of flowCommon StockSEC:0001694665-23-000004:0
1,250 shares@ €1.756218.0% of flowCommon StockSEC:0001694665-22-000132:0
1,250 shares@ €3.589850.0% of flowCommon StockSEC:0001694665-22-000029:0
3 of 3 declarations
